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Microbial Ecology of the Murine Gut Associated with the
Development of Dextran Sodium Sulfate-Induced Colitis
Nabeetha A. Nagalingam, MPhil,* John Y. Kao, MD,† and Vincent B. Young, MD, PhD‡,§
Background: Dextran sodium sulfate (DSS) is used to induce mu-
rine colitis. Although the exact mechanism by which DSS adminis-
tration causes disease is unknown, evidence suggests that the resident
bacteria play a role in the development of murine DSS colitis, analo-
gous to their role in human inflammatory bowel diseases.
Methods: C57BL/6 mice received 5% DSS in the drinking water
and were euthanized 3 days and 14 days after the initiation of
DSS treatment. Culture-independent methods were used to follow
changes in the community structure of the gut’s microbiota fol-
lowing DSS treatment. Histologic evidence of disease and
changes in host gene expression were assessed.
Results: Histologic colitis was minimal in DSS-treated animals at 3
days, but severe after 14 days. Analysis of 16S rRNA-encoding gene
clone libraries demonstrated that the microbial communities in the
ceca of DSS-treated mice were distinct from those in control mice.
The microbiota in the cecum of DSS-treated animals was character-
ized by an overall decrease in microbial richness, an increase in
members of the phylum Verrucomicrobia, and decrease in Teneri-
cutes. Changes in the host’s inflammatory response and microbial
communities occurred before the histologic appearance of severe dis-
ease in the colon, but were seen concurrently in the cecum.
Conclusions: DSS administration is associated with reproducible
changes in the gut microbial diversity of mice. Microbial and
immunological changes appeared before the development of severe
inflammation in the colon. This indicates that these changes in mi-
crobial community may play role in the potentiation of the abnor-
mal inflammatory response seen in DSS-treated animals.
(Inflamm Bowel Dis 2011;17:917–926)
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M icrobes are essential to the health and well-being oftheir hosts.1,2 However, the presence of bacteria
alone is not enough to impart these benefits; rather, the
composition and relative abundance of specific microbes
have an important role in maintaining health.3 Alterations
of the community structure of the indigenous microbiota
have also been implicated in the development of disease.
One such condition in which the resident bacteria are
thought to play a critical role in pathogenesis is inflamma-
tory bowel disease (IBD).3,4 Dysbiosis, defects in immu-
noregulation, and defects in the barrier function are all
thought to contribute to the onset of disease.5–7 Evidence
of a key role for the microbiota in pathogenesis is provided
by studies that demonstrate that antibiotics can reduce or
prevent inflammation both in patients and in murine mod-
els of disease.8,9 In IL10/ mice, which develop colitis af-
ter infection with certain bacteria or in the setting of cer-
tain housing conditions, treatment with antibiotics is
associated with alterations in the microbial gut commu-
nity,10 and the prevention or amelioration of disease.11
Of the multiple murine models of IBD, one com-
monly used system involves the administration of dextran
sodium sulfate (DSS), which induces disease very similar
to human ulcerative colitis.12 Antibiotic administration has
been shown to ameliorate DSS-induced colitis13 and cathe-
licidin, an antimicrobial peptide, was also found to have
protective effects in this model of colitis,14 indicating that
the microbiota plays a role in this disease model system.
Multiple hypotheses have been postulated for the
mechanism by which DSS triggers gut mucosal inflamma-
tion but the exact pathogenesis remains unclear.14,15 Given
that human IBD is associated with an altered microbial di-
versity5,16 and evidence for a role of the microbiota in
DSS-induced colitis,14,17 we hypothesize that this model is
also associated with an altered diversity of the intestinal
microbiota. To test whether DSS treatment can alter the
microbial community diversity we employed molecular
techniques targeting the 16S rRNA-encoding gene to fol-
low the community structure of the gut bacteria in animals
receiving DSS. We correlated changes in the community
structure with development of disease and host responses.
Additional supporting information may be found in the online version
of this article.
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MATERIALS AND METHODS
Animals
C57BL/6 mice from a breeding colony initially estab-
lished with breeding stock from Jackson Laboratories (Bar
Harbor, ME) were used for experiments. The animal stud-
ies were conducted at Michigan State University and were
approved by the Michigan State University Ethics Commit-
tee. Mice were housed with autoclaved bedding, given ster-
ile food and water ad libitum, and exposed to 12:12-hour
light:dark cycles. The mice, between 12 to 16 weeks old,
were assigned to cages according to gender. DSS (36,000–
50,000 MW, ICN Biochemicals, Irvine, CA) was adminis-
tered as a 5% solution in the drinking water.8
Three groups of mice were used in the experiment: 10
control mice that were maintained on sterile drinking water;
10 mice that were placed on 5% DSS in sterile drinking
water for 3 days before being euthanized; and 11 mice that
were given 5% DSS for 14 days before euthanasia.18
Necropsy and Histology
The mice were euthanized by CO2 asphyxiation and
the cecal tissue harvested as described previously.19 The
tissues were gently washed with 1 phosphate-buffered
saline (PBS) to remove the fecal contents, cut into sections,
and snap-frozen in liquid nitrogen. One of these sections
was used for terminal restriction fragment length polymor-
phism (T-RFLP) analyses and clone library analysis, and
another for RNA extraction.
The remainder of the ceca was processed for histol-
ogy as follows: The luminal contents were removed,
washed with PBS, placed in tissue cassettes, and sub-
merged in 10% formalin for 24 hours. The tissue cassettes
were transferred to a 60% ethanol solution and then proc-
essed for paraffin embedding and staining with hematoxylin
and eosin (H&E).
Scoring was completed using the colitis index histo-
logical scoring system used by Berndt et al20 and adapted
from Rachmilewitz et al.21 Briefly, the sections assessed on
inflammation, transmural infiltration, cell wall thickening,
and bleeding and scored on a scale ranging from 0 to 40.
RNA Extraction and Polymerase Chain Reaction
(PCR) Array Analysis
Total RNA from cecal tissue was isolated using
TRIzol (Invitrogen, Carlsbad, CA) as directed by the manu-
facturer’s protocol. The High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA)
was used to convert the total RNA to cDNA. Changes in
host gene expression were measured using an array of
gene-specific primers from Superarray (Frederick, MD),
designed for the following targets22: Jun, Cd80, Cd209a,
Il12b, Irak3, Smad3, Arg1, Cd86, Mapk3, Il17a, Mapk8,
Tgfb1, Cd274, Creb1, Mapk1, Il1b, Tlr2, Tlr5, Vtcn1,
Cx3cr1, Foxp3, Il2, Tlr4, Tlr9, Ccr2, Cxcl1, Tnfrsf18,
Il23a, H2-DMb1, Tnf, Ccr7, Cxcl10, Infg, Il4, Nfkb1,
Vegfa, Itgax, Cxcl5, Il10, Il6, Mapk14, Gapdh, Cd40,
Cxcl2, Il12a, Irak4, Pik3r1, ActB. The neutrophil marker,
Ly-6G, was also quantified using the primer set from
Sasmono et al23 (Ly-6G forward primer 50-TGGACTCT
CACAGAAGCAAAG-30 and reverse primer 50-GCAGA
GGTCTTCCTTCCAACA-30) as well as the Gapdh primer
set from Cui et al24 (forward primer 50-ACCACAGTC
CATGCCATCAC-30 and reverse primer 50-TCCAC
CACCCTGTTGCTGTA-3). Quantization was performed
using LightCycler 480 SYBR Green I Master and analyzed
on a LightCycler 480 system (Roche Diagnostics, Indianap-
olis, IN) as directed by the manufacturer’s protocol, with
the following cycling conditions: 95C activation for 10
minutes; 40 cycles of 95C denaturation for 15 seconds,
and 60C annealing for 1 minute. Resulting threshold val-
ues were analyzed by calculating the 2-DDCt values, using
GAPDH as the reference, to find fold regulation compared
to the no-DSS control.25–27
DNA Extraction
Genomic DNA was extracted from tissue using the
Qiagen DNeasy Blood & Tissue kit (Cat. No. 69504, Va-
lencia, CA). Briefly, the tissue was incubated overnight in
lysis buffer and proteinase K at 56C. The following day
the enzyme was denatured at 95C and DNA was purified
using ethanol through filter columns, as directed by the
manufacturer’s protocol, and eluted in 30 lL of elution
buffer. This genomic DNA was then used in preparation of
the clone libraries and T-RFLP.
Clone Library Construction
For clone library construction, the reaction was set
up as described previously,28 with illustra PuReTaq Ready
To Go PCR beads (GE Healthcare, Piscataway, NJ).
Briefly, amplification by polymerase chain reaction was
performed using broad-ranged primers, (8F, 50-AGAGTTT
GATCCTGGCTCAG-30; 1492R, 50-GGTTACCTTGTTAC
GACTT-30). Amplicon purification was done using a com-
mercial kit (GFX, GE Healthcare, Piscataway, NJ) as
directed by the manufacturer. Products were ligated into
the TOPO 4 vector (Invitrogen K4575-01) according to the
manufacturer’s specifications, and transformed into Esche-
richia coli. Colonies were picked into Luria Broth (LB)
with carbenicillin (50 lg/mL) and grown overnight at
37C. Vector specific primers (M13F, 50-CAGTCACGA
CGTTGTAAAACGACGGC-30; and M13R, 50-CAGGA
AACAGCTATGACCATG-30) were used to screen these
colonies for bacterial clones containing the appropriate 1.5
kb amplicon insert. Partial 16S sequences were determined
by a single sequencing run using the 8F primer at the
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Genomic Core at Michigan State University. Raw sequence
data were processes through an automated ‘‘information
pipeline’’ available through the Ribosomal Database Project
(RDP) Website (http://rdp.cme.msu.edu/). Data were
screened using the Chimera Check Program before upload-
ing into the RDP. Following alignment of the sequences
via myRDP29 distance matrices representing each of the
libraries were downloaded and then taxonomic assignments
designated (80% confidence cutoff) using Classifier through
the RDP website. These distance matrices were also input
into mothur30 to be grouped into operational taxonomic
units (OTUs). Analyses were done using a 97% sequence
similarity to denote species level. An input table was also
generated for the EstimateS program via the RDP Pipeline.
EstimateS31 was used to calculate ecological diversity indi-
ces from the aligned sequences. Dendrograms based on the
Bray–Curtis similarity index were constructed using the
Mega3 program.32
The 16S small subunit rRNA gene sequences
obtained by clone library analysis were subjected to in sil-
ico T-RFLP analysis using the TRF-cut program in the
ARB suite of programs.33 The MspI enzyme, a four base
cutter, was used to calculate predicted terminal restriction
fragments (TRFs) from the clone sequences. Histograms
were then constructed displaying the relative abundance of
these in silico generated TRFs and compared to the actual
traces retrieved from the T-RFLP analysis described below.
The fragment sizes obtained by T-RFLP analysis were
compared to the sizes of the TRFs generated in silico from
the cloned 16S sequences. These fragments were identified
within two basepairs (62 bp) of the predicted TRFs.34
T-RFLP Analysis
T-RFLP was performed as described elsewhere35 using
primers 1492R and FAM labeled 8F. In summary, genomic
DNA was amplified using the aforementioned primers with
PCR conditions: 94C denaturation for 2 minutes; 30 cycles
of denaturation at 94C for 30 seconds; annealing at 58C for
45 seconds; extension at 72C for 90 seconds; and final exten-
sion at 72C for 4 minutes. The 1.5-kb PCR product was veri-
fied and purified with GFX columns (GFX, GE Healthcare),
then subjected to digestion with the MspI restriction enzyme
for 2 hours. The digested DNA was submitted for analysis to
the Genome Technology Support Facility (GTSF) at Michigan
State University. Traces were visualized using the program
Genescan (Applied Biosystems).
T-RFLP Stats collection of programs (http://styx.ibest.
uidaho.edu/ibest/research.html)36 were used to analyze the
traces from the T-RFLP output data. Briefly, the peaks of
each trace were binned into OTUs to produce data catego-
rized by both OTUs and abundance. This was then used as
input for the EstimateS (http://viceroyeebuconnedu/esti-
mates)31 program where the Bray-Curtis values were calcu-
lated and used to compare the diversity among the commun-
ities. The Mega3 program32 was used to construct
dendrograms showing the relationship between community
structures using the Bray–Curtis values. The significance dif-
ferences between the community structures were calculated
using the parsimony test from the mothur suite of programs.
qPCR Analysis of Microbial Communities
The quantity of 16S rRNA operons in the samples rela-
tive to a single-copy host gene was measured using a primer/
probe set that targets a broad range of rRNA-encoding gene
sequences (50-TCCTACGGGAGGCAGCAGT-30), the reverse
primer (50-GGACTACCAGGGTATCTAATCCTGTT-30),
and the probe (50-[6-FAM]-203CGTATTACCGCGGCTG
CTGGCAC-[TAMRA]-30).37 A primer/probe set targeting a
264-bp portion of the tumor necrosis factor alpha (TNF-a)
gene was used as a reference using 200 nanomoles of the
forward (TNFa_mu_se; 50-GGCTTTCCGAATTCACTG
GAG-30) and reverse primers (TNFa_mu_as; 50-CCCCGG
CCTTCCAAATAAA-30), and 100 nanomoles of the probe
(TNFa_mu_probe; 50-[Cy5]-ATGTCCATTCCTGAGTTCTG
CAAAGGGA-[Iowa Black RQ]-30).38 The reaction mix con-
sists of LightCycler 480 Probes Master reaction mix (Roche)
at 1 concentration, and appropriate primer/probe pair. Ampli-
fication of each gene was done under separate run conditions:
cycling conditions for the 16S target involved an activation
step of 50C for 2 minutes followed by 95C for 10 minutes.
Forty-five cycles was done at 95C for 15 seconds and 60C
for 1 minute before holding. For the TNF reference gene cy-
cling conditions included an activation step of 50C for 2
minutes followed by 95C for 10 minutes and 45 cycles of
95C for 20 seconds and 64C for 30 seconds. Calculations of
2-DDCt were made to compare changes in the amount of 16S
from samples between treatment groups.21,22
Statistical Analysis
The nonparametric Kruskal–Wallis test was used to an-
alyze histological scores. Differences in the abundances of
specific operational taxonomic units among the treatment
groups were analyzed by analysis of variance (ANOVA).
Statistical differences in the dendrograms comparing distan-
ces between microbial communities were calculated using
the parsimony test function in mothur.30 Probability values
less than 0.05 were considered significantly different.
RESULTS
DSS Treatment Leads to Inflammation of the
Murine Intestinal Tract
Wildtype mice were treated with 5% DSS in drinking
water and the gastrointestinal tissue examined histologi-
cally after 3 and 14 days of treatment. All animals survived
the DSS treatment and no significant clinical signs were
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noted. A mild inflammatory infiltrate developed in the cecum
3 days after DSS administration (Fig. 1b), with notable pro-
gression of disease after 14 days characterized the develop-
ment of a massive inflammatory cell infiltrate and severe
edema (Fig. 1c). These changes were significantly different
from the control state (P < 0.05), as well as between the
3-day and 14-day treatment outcomes (Fig. 1g).
Similarly in the colon, a few animals developed mor-
phological and inflammatory changes after 3 days of DSS
treatment, but as a group these changes were not significant
when compared to controls. However, following 14 days of
DSS administration colonic tissue showed evidence of severe
inflammation and edema, which was significantly greater than
controls of animals after 3 days of treatment (Fig. 1h).
Changes in Host Gene Expression Following
DSS Treatment
Using a quantitative PCR array, we found significant
changes in the expression of ten host genes following DSS
treatment (Fig. 2, Supp. Fig. 1). The expression of arginase
FIGURE 1. Histopathology in DSS-treated mice. H&E-stained sections were prepared from the cecum of (a) untreated control
mice (b) mice after 3 days of DSS treatment and (c) after 14 days of DSS. Arrow indicates submucosal edema. H&E sections
were also prepared from colon samples of (d) untreated controls (e) mice after 3 days of DSS treatment (arrow points to
inflammation) and (f ) animals after 14 days of DSS (arrow shows abscess). Histopathologic scores were calculated for sec-
tions from all 31 animals for (g) cecum and (h) colon sections. Statistical analysis was done with the Kruskal–Wallis test. *P <
0.05 **P < 0.001. Initial magnification 40.
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1 began to increase after 3 days and was significantly up-
regulated 7-fold (P < 0.05) after 14 days of DSS admin-
istration. A significant increase in TNF-a was also seen af-
ter 3 days of DSS treatment, with a 12.91-fold upregulation
(P < 0.05), and remained significantly upregulated at the
14-day timepoint.
The other eight genes were downregulated, compared
to untreated controls. They were TLR 5, IL17, Ccr2, Cx3cr1,
Cxcl2, Cd40, Cd80, and Cd209a. TLR 5 had significant
downregulation after 14 days of DSS exposure, as did Cd40
and Cxcl2. Cd80 only showed a significant change after 3
days of DSS and only marginal change after 14 days. Ccr2,
Cx3cr1, Cd209a, and IL17a showed significant downregula-
tion both at the 3-day and 14-day timepoints.
The presence of neutrophils, as indicated by meas-
uring the Ly-6G marker, increased significantly with DSS
treatment with a 7.7 6 1.2-fold increase after 3 days of
DSS administration, and 14.0 6 1.8-fold increase after 14
days of DSS (Supp. Fig. 1).
Shifts in Gut Microbial Diversity Following
DSS Treatment
To obtain an overview of the status of the microbial
community present in the gastrointestinal tract of each of the
animals in this study, 16S T-RFLP analysis was performed
on DNA extracted from cecal tissue. Analysis of the micro-
bial communities in the cecum of all 31 animals in the study
revealed that the structure of the microbial communities
from DSS-treated mice were significantly different from the
non-DSS controls (P < 0.001) (Supp. Fig. 2).
Since T-RFLP provides a broad overview of the com-
munity structure without information regarding changes in
specific organisms, 16S clone libraries were constructed to
further investigate the microbial community in four repre-
sentative mice from each treatment group. A total of 328
partial 16S rRNA-encoding gene sequences were retrieved
from control animals (71, 84, 89, and 84 per animal), 364
sequences from animals 3 days after the initiation of DSS
treatment (88, 92, 93, and 91), and 370 from the animals
treated with 14 days of DSS (92, 94, 89, and 95). Clone
library analysis confirmed the T-RFLP findings, indicating
that the community compositions of the microbiota in
DSS-treated animals were more similar to each other than
they were to those of the control mice (Fig. 3, Supp. Fig.
4). The T-RFLP traces were compared to in silico TRFs of
the clone libraries to verify that the OTUs matched the
traces (Supp. Figs. 5–8). The communities in all DSS-
treated animals were significantly different from those in
the non-DSS controls (P < 0.001 by the parsimony test
implemented in the analysis suite mothur30). Rarefaction
analysis of the clone libraries revealed that DSS treatment
resulted in a decrease in phylotype richness (Supp. Fig. 4).
This finding was also supported by a decrease in the Simp-
son diversity index (1/D) following DSS treatment from
43.0 6 12.1 to 21.3 6 8.3 (3 days) and 19.7 6 7.0 (14
FIGURE 2. Changes in host gene expression after 3 days
(dark bars) or 14 days (gray bars) 6 SD of DSS administra-
tion. Expression levels were compared to expression in tis-
sue from animals not exposed to DSS. Statistical analysis
was done using Student’s t-test. Statistically significant dif-
ferences (P < 0.05) are denoted by asterisks (*).
FIGURE 3. Comparison of the cecal community in control
animals (black triangles) and in animals following 3 days of
DSS treatment (white squares) and 14 days of treatment
(black squares). Using an OTU definition of 97% similarity,
the Bray–Curtis similarity metric was calculated for each
pairwise comparison and then the results displayed in den-
drogram format. Analysis by the parsimony test indicates
that there is a statistically significant (*P < 0.001) difference
between the communities in control animals and in both
groups of DSS-treated animals.
Inflamm Bowel Dis  Volume 17, Number 4, April 2011 Microbial Ecology of Murine Gut and DSS
921
days) (P < 0.05). However, quantitative PCR of the 16S
gene from each treatment group showed that there were no
significant changes in overall bacterial biomass relative to
the non-DSS control (fold change for 3 day DSS ¼ 0.68 6
0.92 SD, 14 day DSS ¼ 0.97 6 0.82 SD).
We analyzed changes in the relative abundance of
specific phylotypes by classification of the 16S rRNA-
encoding gene sequences. DSS treatment resulted in a
decrease in members of the phyla Bacteriodetes and Tener-
icutes. Alterations in the microbial community were also
apparent at lower taxonomic levels. For example, there was
an increase in the unclassified genera under the family
Lachnospiraceae (Fig. 4, Supp. Fig. 3). The majority of
classified phylotypes in animals from all three experimental
FIGURE 4. Changes in the cecal gut microbial community following DSS administration (A) at the phylum level (B) within
the phylum Firmicutes. Analysis was done by ANOVA and statistical significance (P < 0.05) is denoted by asterisks (*).
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groups were members of the phylum Firmicutes, which
include the classes Clostridia, Mollicutes, and Bacilli. The
Bacteriodetes was most abundant in the control animals
and represented to a lesser extent in the DSS-treated groups
(Fig. 4A, Supp. Fig. 3). A striking observation was that
members of the phylum Verrucomicrobiae were detected
only in the DSS-treated mice and not in the control mice
(Fig. 4A).
Among members of the phylum Bacteriodetes the
richness of the population did not change, indicating that
the changes were mainly due to shift in abundances of dif-
ferent bacteria within this phylum. Among the Firmicutes,
the unclassified genera among the families Ruminoccoca-
ceae and Lachnospiraceae were most prevalent. These
groups showed treatment related shifts as seen in the pie
charts of Figure 4B. When analysis was done using 97%
sequence similarity, there was high richness among the
Lachnospiraceae, compared to other major groups within
the Firmicutes (Table 1), indicating increased diversity
within this category (P < 0.05). These groups also showed
treatment-related shifts (Table 1).
DISCUSSION
The indigenous gut microbiota are felt to play a key
role in the pathogenesis of IBD. Much of the evidence for
the involvement of intestinal bacteria in IBD comes from
studies with murine models of disease.39,40 Many of these
models have specific alterations in host defenses ranging
from altered epithelial cell function to altered innate or
adaptive immunity.41–44 These alterations in host defense
result in abnormal interactions between the host and the in-
digenous microbiota that lead to disease.45 Evidence for
this comes from the fact that antibiotic administration
reduces the severity of disease in these models and rederi-
vation of these mice to the germfree state prevents initia-
tion of disease.13,46
Administration of DSS consistently triggers intestinal
inflammation in rodents. Similar to other models, antibiotic
administration has a beneficial effect in the system, again
pointing to a role for the indigenous microbiota in the dis-
ease process.47 The effects of DSS on germfree mice have
been variable. In some strains of mice more severe colitis is
encountered, while early death, without the development of
significant inflammation, is observed in others.48,49 Germfree
IQI/Jic mice have a high mortality rate, compared to conven-
tional mice, when given a concentration of 5% DSS in drink-
ing water.47 These mice died secondary to hemorrhage
within 3 days after DSS treatment, indicating a protective
function of the microbiota against the toxic effects of DSS
on the gut epithelium. These results are consistent with the
finding that antibiotic administration or genetic defects in
TLR signaling also increased mortality in DSS-treated con-
ventional mice.50,51 Differences in these two studies employ-
ing germfree mice likely reflects the differential effects of
the two doses of DSS on the epithelium, but may also reflect
differences in the composition of the microbiota of the con-
ventional control animals. Since specific subsets of the ‘‘nor-
mal’’ microbiota have differing ability to initiate or sustain
experimental colitis,47,52 these results emphasize the impor-
tance of characterizing the changes in the gut community
associated with DSS-induced colitis across time.
Although it was originally suggested that IBD
resulted from infection with an unknown bacterial patho-
gen,53 the more contemporary view is that entire shifts in
the microbial community structure may be the trigger for
disease.5 An altered gut microbial community has been
associated with disease, as shown in human studies and
animal models,54,55 suggesting that there is a change in
abundance of bacteria that are necessary for maintaining
homeostasis.56,57 After administering DSS to mice, we
show that treatment results in changes in microbial com-
munity structure in the gut, also noted by others.51,58 Addi-
tionally, we found that these changes occur early (within 3
days) and are characterized by reduced overall diversity,
while bacterial load remains unchanged. Some community
members are below the limits of detection after DSS treat-
ment, while others increase in abundance, demonstrating a
selective effect of DSS treatment on specific members of
the community. It has been shown that certain bacteria can
depolymerize DSS and thus can grow in a DSS-rich envi-
ronment better than others.59 This may explain the bloom
of Verrucomicrobia that we observed in DSS-treated mice.
This group of microbes, which has been found in mamma-
lian intestine at very low abundances,60 metabolize sulfur
and degrade mucin.61 Therefore, perturbations of the com-
munity can cause previously underrepresented members of
the community to become dominant,62 resulting in shifts in
community structure, as seen in the phylum Bacteriodetes
and families Ruminococcaceae and Lachnospiraceae.
TABLE 1. Distribution of OTUs Across Treatments from
Major Groups Within the Firmicutes
Clostridiales
N ¼ 17 (%)
Ruminococcus
N ¼ 36 (%)
Lachnospiracea
N ¼ 65 (%)
Shared OTUs among
all groups
6 (35) 16 (44) 15 (23)
OTUs in control
group only
4 (24) 8 (22) 13 (20)
OTUs in 3 day DSS
group only
2 (12) 4 (11) 8 (12)
OTUs in 14 day
DSS group only
2 (12) 5 (14) 12 (18)
Shared OTU in
DSS-treated groups
3 (18) 3 (8) 17 (26)
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Another study has profiled the effects of DSS treat-
ment on the microbial community.51 Similar to our study,
it has been noted that shifts in the relative abundances of
specific phylotypes were observed following DSS treat-
ment, although the specific changes were different from
what we observed. One obvious reason for these differen-
ces could be explained by the fact that different anatomic
locations were sampled (cecal mucosa versus distal colonic
contents), as well as length and concentrations of DSS
administration. Additionally, it is likely that the baseline
microbial communities were quite different between the
animals in this study and the animals we used. Recent
reports have demonstrated that the baseline microbiota can
differ in genetically identical animals obtained from differ-
ent sources and these differences can have a profound
effect on host immune responses.63,64
Disease severity in the cecum increased after 3 days
and 14 days post-DSS administration, concurrent with the
changes observed in the microbial community, indicating a
link between the changes in diversity of the microbiota and
disease. Since shifts in the community structure can reduce
beneficial members of the indigenous microbiota that act
to maintain epithelial health, such as the production of
short-chain fatty acids and stimulation of mucin produc-
tion,57,65–68 it is likely that such changes can affect the
host’s inflammatory response.45,69
Others have suggested that DSS-induced colitis
occurs due to breaches in the epithelial barrier with expo-
sure to antigens produced by the luminal microbes.5,70–76
However, there is evidence that the detection of an altered
microbial community is an important factor in the host
response.77,78 Our data indicate that DSS induces changes
in the microbiota, and together with a compromised barrier,
appears to facilitate disease initiation and progression. It
has been shown that the host responds to microbial-associ-
ated molecular patterns (MAMPS) via Toll-like receptors
(TLRs) in the development of colitis.17,40,79 We found a
significant change in TLR 5, the expression of which was
decreased as colitis progressed. It has been previously dem-
onstrated that TLR 5 is downregulated in patients with
severe ulcerative colitis,80 in concurrence with our data.
However, the role of flagella in DSS colitis is not depend-
ent on TLR5,40,81 suggesting that the downregulation is
perhaps a response from the overstimulation from microbes
through the deteriorating epithelial layer.
It is noteworthy that we saw an increase in arginase 1
after 14 days of DSS treatment. This could be due to the
increase of neutrophils after DSS administration, as indicated
by increased expression of the neutrophil marker Ly6-G. Ar-
ginase 1 also has a protective role in the Citrobacter roden-
tium model of colitis where enzyme inhibition aggravated
disease.82 It has been seen that arginase expression increases
with TNF-a/lipopolysaccharides (LPS) stimulation in human
intestinal microvascular endothelial cells.83 With breaches in
the epithelial layer that allows increased stimulation by LPS,
together with an increase in TNF-a as seen here and in other
studies with DSS,73,84 it follows that arginase expression is
likely to be upregulated. Interestingly, although TNF-a
appeared to be downregulated at 14 days compared to 3
days, arginase was upregulated at 14 days compared to 3
days, consistent with the presumed role for this gene product
in the epithelial repair response. To our knowledge, this
study is the first to document the significant increase of this
enzyme in DSS-induced colitis.
Although others have noted changes in the gut micro-
biota following DSS treatment51 after development of disease,
this is the first study to monitor DSS-induced changes in the
intestinal microbiota over time. In this study we not only cor-
roborate that changes in the gut microbial community are
associated with DSS-induced disease, but we also show that
diversity of the microbiota changed as early as after 3 days
and continued to 14 days of DSS administration. Early shifts
in the microbial community were characterized with increases
in abundances of microbes previously undetectable by the
methods used. These altered communities are present at the
onset of inflammation, and maintained as inflammation sever-
ity increased, reinforcing the idea that disease occurs, and per-
sists, in the presence of an altered intestinal community. These
early changes in the microbiota support the view that disturb-
ance of the resident bacterial community structure may have a
very important role in the onset of diseases such as IBD.
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